Extended release products are designed to release their medication in a controlled manner at a predetermined rate, duration, and location to achieve and maintain optimum therapeutic blood levels of a drug. The objective of the study is to formulate and evaluate Ilaprazole Controlled release tablets comparable to the innovator product. F1-F9 formulations were prepared using varying concentrations of super disintegrates like Crospovidone, Croscarmellose sodium and Sodium starch glycolate in different concentrations. Based on the hardness, friability, weight variation, drug content, F6 formulation was found to be optimised. The selected F6 formulation was sub coated with HPMC P 50 and followed by enteric coating with Acryl-EZE-80 (Eudragit L100-55). 3 formulations (F10-F12) were prepared by using coating. Among the three formulations, F11 formulation was found to be best. FTIR studies were carried out to find out drug and excipient compatibility studies, the studies revealed that there were no interactions. DSC studies also carried out to demonstrate any changes in physical forms of the drug molecule.
INTRODUCTION
Ilaprazole is a substituted benzimidazole which is antiulcerous compound known for decreasing gastric acid secretion. This compound, also known as proton pump inhibitor (PPI) is commonly indicated for the treatment of gastric ulcer, peptic ulcer, duodenal ulcers, erosive or ulcerative GERD (Gastro esophageal reflux disease), symptomatic GERD, pathological hypersecretory conditions (Zollinger-Ellison). Ilaprazole is practically insoluble in water, more soluble in alkaline medium as compared to acidic medium. The stability of Ilaprazole is a function of pH; it is rapidly degraded in acid media, and is more stable under alkaline conditions. Therefore exposure of Ilaprazole to the acidic content of the stomach would lead to significant degradation of the drug and hence, reduced bioavailability. Extended release dosage forms are the best formulations which are used for drugs that are destroyed in the gastric fluids, or cause gastric irritation, or are absorbed preferentially in the intestine. Such preparations contain an alkaline core material comprising the active substance, a separating layer and enteric coating layer. 1 Enteric polymer coatings contain ionisable carboxylic groups which shall remain insensitive to the acidic state of the stomach, nevertheless dissolves or disintegrates readily in the alkaline surroundings of the intestine. The different release characteristics of the enteric polymers have profound impact upon the pharmacokinetic parameters of the drug. An Ideal enteric polymer should possess a hydrophilic and hydrophobic monomeric unit. Methacrylic acid and methyl methacrylate could make an ideal hydrophilic and hydrophobic unit respectively.
The aim of present work was to prepare extended release i.e., enteric coated tablets of Ilaprazole by using HPMC-P 50 and Eudragit L 100 in side vented perforated coating pan to prevent degradation in the stomach due to the acidic environment or gastric enzymes and to study the factors affecting the film coating of tablets performed in a perforated pan coater and further optimization of enteric coating formula is done which implicate more significant effects on dissolution profile of tablet. 
MATERIALS AND METHODS

Materials
Preparation of core tablets
Direct compression method: The core tablets of Ilaprazole formulations were prepared by direct compression method. All the ingredients were accurately weighed, milled and passed through sieve no. 60 (250 microns) to get uniformly distributed and uniform sized particles. The ingredients were then blended in a cube mixer for 30 minutes. The homogeneously blended mixture was then compressed on a 10 station tablet punching machine using 6 mm round biconvex punches at a pressure of 4 to 6 kg/cm 2 . All the formulations were prepared with similar blending time and compaction conditions. [2] [3] [4] [5] [6] [7] The composition of the core tablets is shown in Table. 1. Ingredients  F1  F2  F3  F4  F5  F6  F7  F8  F9  1  Ilaprazole  10  10  10  10  10  10  10  10  10  2  Sodium Carbonate  14  14  14  14  14  14  14  14  14  3 CP 
RESULTS AND DISCUSSION
Compatibility Studies-FTIR:
Drug excipient compatibility study was done by IR. The IR spectrum of Ilaprazole and physical mixture of drug and excipient were recorded using Bruker. The pellets were prepared in KBr press using physical mixture of drug, excipient and KBr. The compatibility and interactions between Ilaprazole and adjuvants were checked using differential scanning calorimetry (DSC). Any possible drug polymer interaction can be studied by thermal analysis. The DSC study was performing on pure drug (Ilaprazole) and Optimized
Formulations. The study was carried out using Hitachi 6300. The 2 mg of sample were heated in a hermetically sealed aluminum pans in the temperature range of 30-220ºC at heating rate of 10ºc /min under nitrogen flow of 40ml/min. Finally hence their no interaction was found between drug and the Adjuvents. 
CONCLUSION
The conclusions of the present research work are as follows:
 The objective of the study is to formulate and evaluate Ilaprazole Extended Release tablets comparable to the innovator product.
 IR spectra indicated the absence of probable chemical interaction between the drug and polymers used in three different proportions.
 F1-F9 formulations (core tablets) were prepared using varying concentrations of super disintegrates.
 Based on the hardness, weight variation, friability, drug content, F6 formulation was found to be optimized.
 The selected F6 formulation was coated with the pH dependent polymers such as acrylic acid derivatives.
 3 formulations (F10, F11, and F12) were prepared by using enteric coating materials.
 Among the three formulations, F11 formulation was found to be best based on dissolution parameters.
 Under the study of kinetic models, Four models have been studied namely Zero Order, First Order, Higuchi, Korsmeyer's-Peppas model. It was found that the drug release followed Zero order kinetic having maximum R 2 value is 0.98. 
